Detalhe da pesquisa
1.
A convenient and practical index for predicting the induction response in adult patients with hemophagocytic lymphohistiocytosis: ferritin/platelet ratio.
Ann Hematol
; 103(3): 715-723, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197929
2.
Outcomes of allogeneic hematopoietic stem cell transplantation for primary hemophagocytic lymphohistiocytosis in adults.
Hematol Oncol
; 40(3): 390-399, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35526261
3.
Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives.
Expert Opin Biol Ther
; 23(10): 1005-1013, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37614018
4.
Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.
Ann Med
; 55(1): 89-100, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36533966
5.
Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation.
J Cancer Res Clin Oncol
; 149(11): 8521-8533, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37093345
6.
A Study on Early Death Prognosis Model in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.
J Healthc Eng
; 2022: 6704859, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35812895
7.
Serum ferritin is a good indicator for predicting the efficacy of adult HLH induction therapy.
Ann Med
; 54(1): 283-292, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35112955
8.
Macrophage activation syndrome in adults: Characteristics, outcomes, and therapeutic effectiveness of etoposide-based regimen.
Front Immunol
; 13: 955523, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36189240
9.
Clinical Features and Prognostic Risk Prediction of Non-Hodgkin Lymphoma-Associated Hemophagocytic Syndrome.
Front Oncol
; 11: 788056, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34938663
10.
Sarocladium strictum meningoencephalitis in a hemophagocytic lymphohistiocytosis patient.
J Infect
; 87(5): 473-475, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36913986
11.
Effectiveness of a modified doxorubicin-etoposide-methylprednisolone regimen for the treatment of refractory or relapsed macrophage activation syndrome in adults.
Pol Arch Intern Med
; 132(3)2022 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35253415